FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969231155> ?p ?o ?g. }

• W2969231155 abstract "BackgroundMosquitoes become infected with Plasmodium when they ingest gametocyte-stage parasites from an infected person's blood. Plasmodium falciparum gametocytes are sensitive to the drug primaquine (PQ) and other 8-aminoquinolines (8AQ); these drugs could prevent parasite transmission from infected people to mosquitoes, and consequently reduce the incidence of malaria. However, PQ will not directly benefit the individual, and could be harmful to those with glucose-6-phosphate dehydrogenase (G6PD) deficiency.In 2010, The World Health Organization (WHO) recommended a single dose of PQ at 0.75 mg/kg, alongside treatment for P. falciparum malaria to reduce transmission in areas approaching malaria elimination. In 2013 the WHO revised this to 0.25 mg/kg due to concerns about safety.ObjectivesTo assess whether giving PQ or an alternative 8AQ alongside treatment for P. falciparum malaria reduces malaria transmission, and to estimate the frequency of severe or haematological adverse events when PQ is given for this purpose.Search methodsWe searched the following databases up to 10 Feb 2014 for trials: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; MEDLINE; EMBASE; LILACS; metaRegister of Controlled Trials (mRCT); and the WHO trials search portal using 'malaria*', 'falciparum', and 'primaquine' as search terms. In addition, we searched conference proceedings and reference lists of included studies, and contacted researchers and organizations.Selection criteriaRandomized controlled trials (RCTs) or quasi-RCTs comparing PQ (or alternative 8AQ) given as a single dose or short course alongside treatment for P. falciparum malaria with malaria treatment given without PQ/8AQ in adults or children.Data collection and analysisTwo authors independently screened all abstracts, applied inclusion criteria, and extracted data. We sought evidence of an impact on transmission (community incidence), infectiousness (mosquitoes infected from humans) and potential infectiousness (gametocyte measures). We calculated the area under the curve (AUC) for gametocyte density over time for comparisons for which data were available. We sought data on haematological and other adverse effects, as well as secondary outcomes of asexual clearance time and recrudescence. We stratified by whether the malaria treatment regimen included an artemisinin derivative or not; by PQ dose category (low < 0.4 mg/kg; medium ≥ 0.4 to < 0.6 mg/kg; high ≥ 0.6 mg/kg); and by PQ schedules. We used the GRADE approach to assess evidence quality.Main resultsWe included 17 RCTs and one quasi-RCT. Eight studies tested for G6PD status: six then excluded participants with G6PD deficiency, one included only those with G6PD deficiency, and one included all irrespective of status. The remaining ten trials either did not report on whether they tested (8), or reported that they did not test (2). Nine trials included study arms with artemisinin-based malaria treatment regimens, and eleven included study arms with non-artemisinin-based treatments.Only two trials evaluated PQ given at low doses (0.25 mg/kg in one and 0.1 mg/kg in the other).PQ with artemisinin-based treatments: No trials evaluated effects on malaria transmission directly (incidence, prevalence, or entomological inoculation rate), and none evaluated infectiousness to mosquitoes. For potential infectiousness, the proportion of people with detectable gametocytaemia on day eight was reduced by around two thirds with high dose PQ category (RR 0.29, 95% CI 0.22 to 0.37, seven trials, 1380 participants, high quality evidence), and with medium dose PQ category (RR 0.34, 95% CI 0.19 to 0.59, two trials, 269 participants, high quality evidence), but the trial evaluating low dose PQ category (0.1 mg/kg) did not demonstrate an effect (RR 0.67, 95% CI 0.44 to 1.02, one trial, 223 participants, low quality evidence). Reductions in log(10)AUC estimates for gametocytaemia on days 1 to 43 with medium and high doses ranged from 24.3% to 87.5%. For haemolysis, one trial reported percent change in mean haemoglobin against baseline, and did not detect a difference between the two arms (very low quality evidence).PQ with non-artemisinin treatments: No trials assessed effects on malaria transmission directly. Two small trials from the same laboratory evaluated infectiousness to mosquitoes, and report that infectivity was eliminated on day 8 in 15/15 patients receiving high dose PQ compared to 1/15 in the control group (low quality evidence). For potential infectiousness, the proportion of people with detectable gametocytaemia on day 8 was reduced by around half with high dose PQ category (RR 0.44, 95% CI 0.27 to 0.70, three trials, 206 participants, high quality evidence), and by around a third with medium dose category (RR 0.62, 0.50 to 0.76, two trials, 283 participants, high quality evidence), but the single trial using low dose PQ category did not demonstrate a difference between groups (one trial, 59 participants, very low quality evidence). Reduction in log(10)AUC for gametocytaemia days 1 to 43 were 24.3% and 27.1% for two arms in one trial giving medium dose PQ. No trials systematically sought evidence of haemolysis.Two trials evaluated the 8AQ bulaquine, and suggest the effects may be greater than PQ, but the small number of participants (n = 112) preclude a definite conclusion.Authors' conclusionsIn individual patients, PQ added to malaria treatments reduces gametocyte prevalence when given in doses greater than 0.4 mg/kg. Whether this translates into preventing people transmitting malaria to mosquitoes has rarely been tested in controlled trials, but there appeared to be a strong reduction in infectiousness in the two small studies that evaluated this. No included trials evaluated whether this policy has an impact on community malaria transmission either in low-endemic settings approaching elimination, or in highly-endemic settings where many people are infected but have no symptoms and are unlikely to be treated.For the currently recommended low dose regimen, there is little direct evidence to be confident that the effect of reduction in gametocyte prevalence is preserved.Most trials excluded people with G6PD deficiency, and thus there is little reliable evidence from controlled trials of the safety of PQ in single dose or short course." @default.
• W2969231155 created "2019-08-29" @default.
• W2969231155 creator A5007223498 @default.
• W2969231155 creator A5058758557 @default.
• W2969231155 creator A5073966797 @default.
• W2969231155 date "2014-06-30" @default.
• W2969231155 modified "2023-09-24" @default.
• W2969231155 title "Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission (Review)" @default.
• W2969231155 hasPublicationYear "2014" @default.
• W2969231155 type Work @default.
• W2969231155 sameAs 2969231155 @default.
• W2969231155 citedByCount "1" @default.
• W2969231155 countsByYear W29692311552015 @default.
• W2969231155 crossrefType "journal-article" @default.
• W2969231155 hasAuthorship W2969231155A5007223498 @default.
• W2969231155 hasAuthorship W2969231155A5058758557 @default.
• W2969231155 hasAuthorship W2969231155A5073966797 @default.
• W2969231155 hasConcept C126322002 @default.
• W2969231155 hasConcept C168563851 @default.
• W2969231155 hasConcept C197934379 @default.
• W2969231155 hasConcept C203014093 @default.
• W2969231155 hasConcept C2776478404 @default.
• W2969231155 hasConcept C2776793103 @default.
• W2969231155 hasConcept C2777199930 @default.
• W2969231155 hasConcept C2777425658 @default.
• W2969231155 hasConcept C2778048844 @default.
• W2969231155 hasConcept C2778371730 @default.
• W2969231155 hasConcept C535046627 @default.
• W2969231155 hasConcept C71924100 @default.
• W2969231155 hasConcept C95190672 @default.
• W2969231155 hasConcept C98274493 @default.
• W2969231155 hasConcept C99389464 @default.
• W2969231155 hasConceptScore W2969231155C126322002 @default.
• W2969231155 hasConceptScore W2969231155C168563851 @default.
• W2969231155 hasConceptScore W2969231155C197934379 @default.
• W2969231155 hasConceptScore W2969231155C203014093 @default.
• W2969231155 hasConceptScore W2969231155C2776478404 @default.
• W2969231155 hasConceptScore W2969231155C2776793103 @default.
• W2969231155 hasConceptScore W2969231155C2777199930 @default.
• W2969231155 hasConceptScore W2969231155C2777425658 @default.
• W2969231155 hasConceptScore W2969231155C2778048844 @default.
• W2969231155 hasConceptScore W2969231155C2778371730 @default.
• W2969231155 hasConceptScore W2969231155C535046627 @default.
• W2969231155 hasConceptScore W2969231155C71924100 @default.
• W2969231155 hasConceptScore W2969231155C95190672 @default.
• W2969231155 hasConceptScore W2969231155C98274493 @default.
• W2969231155 hasConceptScore W2969231155C99389464 @default.
• W2969231155 hasLocation W29692311551 @default.
• W2969231155 hasOpenAccess W2969231155 @default.
• W2969231155 hasPrimaryLocation W29692311551 @default.
• W2969231155 hasRelatedWork W1543465721 @default.
• W2969231155 hasRelatedWork W1545485415 @default.
• W2969231155 hasRelatedWork W1549510969 @default.
• W2969231155 hasRelatedWork W1825014948 @default.
• W2969231155 hasRelatedWork W1945783329 @default.
• W2969231155 hasRelatedWork W1953188892 @default.
• W2969231155 hasRelatedWork W2029623668 @default.
• W2969231155 hasRelatedWork W2060739950 @default.
• W2969231155 hasRelatedWork W2096600825 @default.
• W2969231155 hasRelatedWork W2112170150 @default.
• W2969231155 hasRelatedWork W2122468262 @default.
• W2969231155 hasRelatedWork W2139772492 @default.
• W2969231155 hasRelatedWork W2793811600 @default.
• W2969231155 hasRelatedWork W2795852494 @default.
• W2969231155 hasRelatedWork W2884033046 @default.
• W2969231155 hasRelatedWork W2899942752 @default.
• W2969231155 hasRelatedWork W2918599610 @default.
• W2969231155 hasRelatedWork W3092866484 @default.
• W2969231155 hasRelatedWork W3143367749 @default.
• W2969231155 hasRelatedWork W2289079317 @default.
• W2969231155 isParatext "false" @default.
• W2969231155 isRetracted "false" @default.
• W2969231155 magId "2969231155" @default.
• W2969231155 workType "article" @default.